Julio Flamini
Neurology · Atlanta, GANPI 1437225737
Payments from drug & device makers
Across 2,066 payments — averaging $781.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$542K
- SK Life Science, Inc.$302K
- UCB, Inc.$177K
- Aquestive Therapeutics, Inc.$108K
- Zogenix Inc.$77K
- Supernus Pharmaceuticals, Inc.$71K
- plus $339K from 54 others
Across 20 payments — averaging $1127.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Purdue Pharma L.p.$16K
- Teva Pharmaceuticals USA, Inc.$5K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,613,828 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.
Other neurology in Atlanta
- James LahAtlanta$6.8M
- Jonathan GlassAtlanta$5.1M
- Allan LeveyAtlanta$4.2M
- Ben ThrowerAtlanta$3.7M
- Jeffrey EnglishAtlanta$3.1M
- Dennis LaceyAtlanta$2.8M
- Joash LazarusAtlanta$1.4M
- Frank BerensonAtlanta$1.2M
- Stewart FactorAtlanta$1M
- Matthews GwynnAtlanta$775K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.